|
"許駿"的相關文件
顯示項目 11-20 / 148 (共15頁)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2018-09-10T07:19:44Z |
Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival
|
Shen, Y.-C. and Hu, F.-C. and Jeng, Y.-M. and Chang, Y.-T. and Lin, Z.-Z. and Chang, M.-C. and Hsu, C. and Cheng, A.-L.; 沈盈君;胡賦強;鄭永銘;張毓廷;林宗哲;章明珠;許駿;鄭安理; SHEN, YING-CHUN;HU, FU-CHANG;JENG, YUNG-MING;CHANG, YU-TING;LIN, ZONG-ZHE;CHANG, MING-CHU;HSU, CHIUN;CHENG, ANN-LII; YUNG-MING JENG; YU-TING CHANG; ANN-LII CHENG; SHEN, YING-CHUN; HU, FU-CHANG; JENG, YUNG-MING; CHANG, YU-TING; LIN, ZONG-ZHE; CHANG, MING-CHU; HSU, CHIUN; CHENG, ANN-LII |
| 國家衛生研究院 |
2017 |
探討醛酮還原?1B10及其代謝產物參與肝細胞癌上皮細胞間質轉化及抗藥性之角色
|
劉俊揚;許駿;柯博升;郭呈欽;鄭靜枝;詹以吉 |
| 國立臺灣大學 |
2016 |
Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression
|
Hsu, Chiun; Lin, Liang-In; Cheng, Yu-Che; Feng, Zi-Rui; Shao, Yu-Yun; Cheng, Ann-Lii; Ou, Da-Liang; 邵幼雲; 林亮音; 鄭安理; 許駿; 歐大諒 |
| 國立臺灣大學 |
2016 |
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer
|
Yang, Shih-Hung; Kuo, Ting-Chun; Wu, Hsu; Guo, Jhe-Cyuan; Hsu, Chiun; Hsu, Chih-Hung; Tien, Yu-Wen; Yeh, Kun-Huei; Cheng, Ann-Lii; Kuo, Sung-Hsin; 郭頌鑫; 鄭安理; 徐志宏; 許駿; 葉坤輝; 郭哲銓; 田郁文; 郭庭均; 楊士弘 |
| 國立臺灣大學 |
2016 |
Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer
|
Chiang, Nai-Jung; Hsu, Chiun; Chen, Jen-Shi; Tsou, Hsiao-Hui; Shen, Ying-Ying; Chao, Yee; Chen, Ming-Huang; Yeh, Ta-Sen; Shan, Yan-Shen; Huang, Shiu-Feng; Chen, Li-Tzong; 許駿 |
| 國立臺灣大學 |
2016 |
Dynamic Contrast-enhanced MR Imaging of Advanced Hepatocellular Carcinoma: Comparison with the Liver Parenchyma and Correlation with the Survival of Patients Receiving Systemic Therapy
|
Chen, Bang-Bin; Hsu, Chao-Yu; Yu, Chih-Wei; Liang, Po-Chin; Hsu, Chiun; Hsu, Chih-Hung; Cheng, Ann-Lii; Shih, Tiffany Ting-Fang; 許昭禹; 鄭安理; 陳邦斌; 徐志宏; 許駿; 梁博欽; 游治維 |
| 國立臺灣大學 |
2016 |
Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges
|
Lu, Li-Chun; Hsu, Chih-Hung; Hsu, Chiun; Cheng, Ann-Lii; 鄭安理; 徐志宏; 許駿; 呂理駿 |
| 國立臺灣大學 |
2016 |
Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study
|
Melero, I.; Sangro, B.; Yau, T.; Hsu, C.; Kudo, M.; Crocenzi, T.; Kim, T-Y.; Choo, S-P.; Trojan, J.; Meyer, T.; Welling, T. H., III; Yeo, W.; Chopra, A.; Anderson, J.; Dela Cruz, C.; Lang, L.; Neely, J.; El-Khoueiry, A.; 許駿 |
| 國立臺灣大學 |
2016 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma (HCC): biomarker exploration
|
Shao, Y-Y.; Chen, B-B.; Lin, Z-Z.; Hsu, C-H.; Wang, M-J.; Cheng, A-L.; Hsu, C.; 邵幼雲; 林宗哲; 鄭安理; 陳邦斌; 徐志宏; 許駿 |
| 國家衛生研究院 |
2016 |
肝細胞癌中ZNF479所調控之第一型金屬硫蛋白作為抗藥性標的物及抗癌藥物篩選平台之探討與應用
|
劉俊揚;詹以吉;鄭靜枝;許駿;柯博升 |
顯示項目 11-20 / 148 (共15頁)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目
|
